Reborn Coffee, Inc. (REBN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Reborn Coffee, Inc., a Delaware corporation, on February 23, 2026, covering events occurring on February 19 and February 20, 2026. The Company's common stock trades on the Nasdaq Capital Market under the symbol "REBN."
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to a prior transaction: on October 20, 2025, the Company issued 1,192,661 shares of common stock to new director Charles C. Jeong for an aggregate purchase price of $6,500,000 ($5.45 per share).
Material Changes
- Nasdaq Compliance Notice: On February 19, 2026, the Company received a notification from Nasdaq stating it no longer complies with Listing Rule 5605 regarding independent director, audit committee, and compensation committee requirements.
- Board Composition Changes: On February 20, 2026, the Board size was reduced from seven to six members following the resignations of Andy Nasim, Alex Go, and Mi Young Jeong.
- Director Appointments: Charles C. Jeong and Mi Jeong Lee were appointed to fill the vacancies. Both are deemed independent. Mr. Jeong will chair the Compensation Committee, and Ms. Lee will serve on the Audit Committee.
- Remediation: The Company states that the appointment of Mr. Jeong and Ms. Lee has remedied all deficiencies under Nasdaq Listing Rule 5605.
Outlook, Risks, and Contingencies
While the Company asserts it has remedied the deficiencies, Nasdaq has granted a cure period to formally evidence compliance. This period extends until the earlier of the next annual stockholders' meeting or February 13, 2027 (or August 12, 2026, if the meeting is held before that date). If compliance is not regained, the Company faces potential delisting. The Company may appeal a delisting determination to a Hearings Panel, though there is no assurance of approval. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of meeting Nasdaq requirements.
Investor Verification Checklist
- Confirm the Company has formally submitted its compliance plan to Nasdaq to officially close the cure period.
- Verify the independence status of the newly appointed directors (Charles C. Jeong and Mi Jeong Lee) in subsequent filings.
- Monitor for any further correspondence from Nasdaq regarding the status of the listing or the cure period.
- Review the Company's most recent Form 10-K or 10-Q for updated financial performance data, as this 8-K contains no operational financial results.